| Literature DB >> 34880636 |
Syeda Ayesha Ali1,2, Muhammad Kamran Taj1, Syeda Hafsa Ali3.
Abstract
INTRODUCTION: Bacterial meningitis (BM) is a lethal infectious disease that persists as a substantial cause of morbidity and mortality. The antimicrobial drug resistance in BM pathogens poses a major threat to the community while raising challenges for clinicians. For the first time, we elucidate the incidence rate of BM and its drug resistance among the population of Quetta, Balochistan.Entities:
Keywords: 16S rRNA; bacterial meningitis; cerebrospinal fluid; drug resistance; incidence rate
Year: 2021 PMID: 34880636 PMCID: PMC8646111 DOI: 10.2147/IDR.S339231
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
The Primer Sequences for Diagnosis of Bacterial Isolates BM Patients
| S. No. | Strain | Primer 16S rRNA | bps | Tm Values | Reference |
|---|---|---|---|---|---|
| 1. | Forward primer= GGGAGTAAAGTTAATACCTTTGC | 204 | 58 | ||
| 2. | Forward primer= CCACACTGGGACTGAGACAC | 598 | 59 | This study | |
| 3. | Forward primer = ACGGTCTTGCTGTCACTTATA | 257 | 57 | ||
| 4. | Forward primer= TCTGAGAGGATGACCAGCCA | 525 | 59 | This study | |
| 5. | Forward primer = TTTTGGACAATGGGCGCAAG | 568 | 59 | This study | |
| 6. | Forward primer = ATACCCTGGTAGTCCACGCT | 528 | 60 | This study |
Figure 1Frequency of positive bacterial meningitis cases.
Demographics of Bacterial Meningitis Infected Patients
| Characteristics | BM Cases n(%) | Non-BM Cases n(%) | Total n(%) | p-value |
|---|---|---|---|---|
| 321 (35.9%) | 573 (64.1%) | 894 (100%) | ||
| Male | 186 (20.8%) | 342 (38.3%) | 528 (59.1%) | 0.611 |
| Female | 135 (15.1%) | 231 (25.8%) | 366 (40.9%) | |
| 1 month- 3 months | 94 (10.6%) | 42 (4.7%) | 136 (15.2%) | 0.001* |
| 4 months- 1 year | 80 (8.9%) | 128 (14.3%) | 208 (23.3%) | |
| 2 years–12 years | 46 (5.1%) | 112 (12.5%) | 158 (17.7%) | |
| 13 years–19 years | 13 (1.5%) | 46 (5.1%) | 59 (6.6%) | |
| 20 years–40 years | 17 (1.9%) | 73 (8.2.4%) | 90 (10.1%) | |
| 41 years–60 years | 20 (2.2%) | 85 (9.5%) | 105 (11.7%) | |
| 61 years–99 years | 51 (5.7%) | 87 (9.7%) | 138 (15.4%) | |
| Rural | 163 (18.2%) | 215 (24.0%) | 378 (42.3%) | 0.001* |
| Urban | 158 (17.7%) | 358 (40.0%) | 516 (57.7%) | |
| Pashtun | 176 (19.7%) | 306 (34.2%) | 482 (53.9%) | 0.343 |
| Baloch | 68 (7.6%) | 113 (12.6%) | 181 (20.2%) | |
| Punjabi | 51 (5.7%) | 117 (13.1%) | 168 (18.8%) | |
| Hazara | 26 (2.9%) | 37 (4.1%) | 63 (7%) | |
| Lower class <20K PKR per month | 173 (19.4%) | 243 (27.2%) | 416 (46.5%) | 0.003* |
| Middle class 21k–50k PKR per month | 119 (13.3%) | 255 (28.5%) | 374 (41.8%) | |
| High class >50k PKR per month | 29 (3.2%) | 75 (8.4%) | 104 (11.6%) | |
| Illiterate | 234 (26.2%) | 361 (40.5%) | 595 (66.6%) | 0.003* |
| Literate | 87 (9.7%) | 212 (23.7%) | 299 (33.4%) | |
| Mortality | 36 (4%) | 13 (1.5%) | 49 (5.5%) | 0.001* |
| Survive | 285 (31.5%) | 560 (63%) | 867 (94.5%) | |
| Case fatality rate | 36 (11%) | – | 36 (11%) | |
| BMCH | 184 (20.6%) | 322 (36.0%) | 506 (56.6%) | 0.745 |
| DHQ | 137 (15.3%) | 251 (28.1%) | 388 (43.4%) | |
Note: *Statistically significant; 20K= 20,000; 50k= 50,000; PKR = Pakistani Rupee.
Abbreviations: BMCH, Bolan Medical Complex Hospital; DHQ, District Hospital Quetta.
Comparative Analysis of Bacterial Culture and Gram Staining Among Bacterial Meningitis Cases
| Test Performed | Bacterial Culture BM Cases | Total | |
|---|---|---|---|
| Positive Cases | Negative Cases | ||
| Gram Staining positive cases | 50 | 0 | 50 |
| Gram Staining negative cases | 271 | 573 | 844 |
| Total | 321 | 573 | 894 |
Incidence Rate of Isolated Bacterial Meningitis Pathogens Among Various Age Groups
| Bacteria Causing Meningitis | Among Various Age Groups | |||||||
|---|---|---|---|---|---|---|---|---|
| 1 Month–3 Months n(%) | 4 Months–1 Year n(%) | 2–12 Years n(%) | 13–19 Years n(%) | 20–40 Years n(%) | 41–60 Years n(%) | 61–90 Years n(%) | Total n(%) | |
| 25 (2.8%) | 12 (1.3%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 3 (0.3%) | 40 (4.5%) | |
| 12 (1.3%) | 9 (1.0%) | 13 (1.5%) | 7 (0.8%) | 6 (0.7%) | 3 (0.3%) | 11 (1.2%) | 61 (6.8%) | |
| 5 (0.6%) | 7 (0.8%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 5 (0.6%) | 17 (1.9%) | |
| 17 (1.9%) | 27 (3.0%) | 32 (3.6% | 6 (0.7%) | 11 (1.2%) | 17 (1.9%) | 20 (2.2%) | 130 (14.5%) | |
| 5 (0.6%) | 8 (0.9%) | 1 (0.1%) | 0 (0%) | 0 (0%) | 0 (0%) | 8 (0.9%) | 22 (2.5%) | |
| 30 (3.4%) | 17 (1.9%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 4 (0.4%) | 51 (5.7%) | |
Prognostic Factors of Bacterial Meningitis Infected Patients
| Characteristics | Total BM Cases n(%)/ Out of 894 | Non-Fatal BM Cases n (%) | Fatal BM Cases n (%) | Odd Ratio | 95% Confidence Interval | ||
|---|---|---|---|---|---|---|---|
| Lower | Upper | ||||||
| Male | 35 (61.4%) | 159 | 27 | 0.512 | 0.634 | 0.0162 | 2.476a |
| Female | 22 (38.6%) | 126 | 9 | ||||
| Within 24hrs | 103 (11.5%) | 89 | 14 | 0.909 | 1.097 | 0.225 | 5.341b |
| After 24hrs | 218 (24.4%) | 196 | 22 | ||||
| 7.32–7.5 | 90 (10.1%) | 69 | 21 | 0.01* | 0.129 | 0.026 | 0.645c |
| 7.6–8 | 231 (25.8%) | 216 | 15 | ||||
| Clear | 120 (13.4%) | 112 | 8 | 0.001* | 22.847 | 3.830 | 136.287d |
| Turbidity | 201 (22.5%) | 173 | 28 | ||||
| 14–45mg/dL | 13 (1.5%) | 11 | 2 | 0.993 | 1.015 | 0.038 | 27.049e |
| > 45mg/dL (Range; 46–2500mg/dL) | 308 (34.5%) | 274 | 34 | ||||
| 45–100mg/dL | 64 (7.2%) | 58 | 6 | 0.449 | 2.205 | 0.285 | 17.058f |
| >100mg/dL (Range; 100–250 mg/dL) | 9 (1%) | 9 | 0 | 0.998. | 6017.95 | 6015.951 | 6021.951f |
| Low ≤45 mg/dL (Range; 0–44 mg/dL) | 248 (27.7%) | 218 | 30 | ||||
| 21 to 100 cells/mm3 | 86 (9.6%) | 73 | 13 | 0.117 | 4.694 | 0.678 | 32.518g |
| 101 to 2000 cells/mm3 | 190 (21.3%) | 178 | 12 | 0.001* | 24.177 | 3.932 | 148.644g |
| ≥2001 cells/mm3 | 45 (5%) | 34 | 11 | ||||
| >10–≥30% | 34 (4%) | 25 | 9 | 0.118 | 0.184 | 0.022 | 1.535h |
| >31–≥60% | 101 (11.1%) | 85 | 16 | 0.476 | 0.572 | 0.123 | 2.656h |
| >61–≥90% | 186 (20.8%) | 175 | 11 | ||||
| Diabetes mellitus | 29 (3.2%) | 23 | 6 | 0.918 | 0.841 | 0.031 | 23.017 |
| Hypertension | 39 (4.4%) | 34 | 5 | 0.944 | 1.082 | 0.119 | 9.855 |
| COPD | 105 (11.7%) | 95 | 10 | 0.337 | 1.862 | 0.524 | 6.625 |
| Liver disease | 33 (3.7%) | 28 | 5 | 0.765 | 0.735 | 0.097 | 5.544 |
| Smoker | 36 (4.02%) | 29 | 7 | 0.220 | 0.092 | 0.002 | 4.170 |
| Severe pneumonia | 155 (17.3%) | 134 | 21 | 0.513 | 0.518 | 0.072 | 3.720 |
| Bacteremia | 161 (18%) | 139 | 22 | 0.861 | 0.853 | 0.145 | 5.028 |
| Sinusitis | 91 (10.2%) | 75 | 16 | 0.557 | 0.633 | 0.138 | 2.906 |
| Endocarditis | 21 (2.3%) | 17 | 4 | 0.05* | 316.44 | 0.810 | 1235 |
| Otitis media | 24 (2.7%) | 21 | 3 | 0.997 | 1.010 | 0.005 | 194.55 |
Notes: arelative to female gender; brelative to antimicrobial therapy not started within 24hrs; crelative to high pH; drelative to turbidity of CSF; erelative to High protein level; frelative to low glucose level; grelative to high WBCs (≥2001 cells/mm3); hrelative to high neutrophils level (>61–≥90%); *=p < 0.05 (significant value).
Figure 2Clinical manifestations of bacterial meningitis patients.
Figure 316S rRNA gene PCR-based identification bacteria isolated from CSF of bacterial meningitis patients. (A) E. coli isolates with 204bp amplified fragments; (B) S. aureus solates 257bp amplified fragments; (C) K. pneumoniae isolates 525bp amplified fragments; (D) S. pneumoniae isolates 598bp amplified fragments; (E) H. influenzae isolates 528bp amplified fragments; (F) N. meningitidis isolates 568bp amplified fragments. M= molecular weight marker (1kb).
Figure 4Phylogenetic relationship of bacterial isolates from bacterial meningitis patients with their reference strains. S. pneumoniae (MW405781, MW405782, MW405783, MW405784, MW405785, MT075569.1); E. coli (MT075572 MT916768, MT916769, MT916770); K. pneumoniae (MW208813, MW208814, MW208815, MW208816, MW208817, MT102939); S. aureus (MW148201.1, MW148202.1, MW148203.1, MW148204.1, MT075573.1); H. influenzae (MZ348556, MZ348557, MZ348558, MZ348559, MZ348560); N. meningitidis (MZ318247, MZ318248, MZ318249, MZ318250, MZ318251) isolated from BM patients of Balochistan were compared using 16S rRNA gene sequence with other reference strains using neighbor-joining phylogenetic tree. The bootstrap values were based on 1000 replicates in MEGA X software.
The Antimicrobial Susceptibility Test Against Bacteria Isolated Bacterial Meningitis Patients
| Bacterial Isolates | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Antibiotics | Conc (µg) | ||||||||||||
| R n/N (%) | S n/N(%) | R n/N(%) | S n/N(%) | R n/N(%) | S n/N(%) | R n/N(%) | S n/N(%) | R n/N(%) | S n/N(%) | R n/N(%) | S n/N(%) | ||
| Amikacin | 30 | 1/40 (2.5%) | 39/40 (97.5%) | 2/17 (11.8%) | 15/7 (88.2%) | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. |
| Amoxicillin | 25 | 32/40 (80%) | 8/40 (20%) | 17/17 (100%) | 0/17 (0%) | 61/61 (100%) | 0/61 (0%) | 130/130 (100%) | 0/130 (0%) | n.a. | n.a. | n.a. | n.a. |
| Ceftazidime | 30 | 7/40 (17.5%) | 33/40 (82.5%) | 11/17 (64.7%) | 6/17 (35.3%) | n.a. | n.a. | n.a. | n.a. | 2/22 (10%) | 20/22 (90%) | n.a. | n.a. |
| Ceftriaxone | 30 | 11/40 (27.5%) | 29/40 (72.5%) | 8/17 (47.1%) | 9/17 (52.9%) | n.a. | n.a. | n.a. | n.a. | 3/22 (13.6%) | 19/22 (86.4%) | 2/51 (3.9%) | 49/51 (96.1%) |
| Ciprofloxacin | 5 | 12/40 (30%) | 28/40 (70%) | 7/17 (41%) | 10/17 (558.8%) | 2/61 (3.3%) | 59/61 (96.7%) | n.a. | n.a. | 1/22 (4.5%) | 21/22 (95.5%) | 4/51 (7.8%) | 47/51 (92.2%) |
| Erythromycin | 15 | 18/40 (45%) | 22/40 (55%) | 15/17 (88.2%) | 2/17 (11.8%) | 55/61 (90.2%) | 6/61 (9.8%) | 84/130 (64.6%) | 46/130 (35.4%) | n.a. | n.a. | n.a. | n.a. |
| Gentamicin | 10 | 7/40 (17.5%) | 33/40 (82.5%) | 6/17 (35.3%) | 11/17 (64.7%) | 13/61 (21.3%) | 48/61 (78.7%) | 35/130 (27%) | 95/130 (73%) | n.a. | n.a. | n.a. | n.a. |
| Levofloxacin | 5 | 5/40 (12.5%) | 35/40 (87.5%) | 6/17 (35.3%) | 11/17 (64.7%) | 16/61 (26.2%) | 45/61 (73.8%) | 0/130 (0%) | 130/130 (100%) | 0/22 (0%) | 22/22 (100%) | n.a. | n.a. |
| Meropenem | 10 | 3/40 (7.5%) | 37/40 (92.5) | 7/17 (41.2%) | 10/17 (58.8%) | n.a. | n.a. | n.a. | n.a. | 0/22 (0%) | 22/22 (100%) | 0/51 (0%) | 51/51 (100%) |
| Oxytetracycline | 30 | 22/40 (55%) | 18/40 (45%) | 15/17 (88.2%) | 2/17 (11.8%) | 40/61 (65.6%) | 21/61 (34.4%) | 27/130 (20.8%) | 103/130 (79.2%) | 5/22 (22.7%) | 17 /22 (77.3%) | n.a. | n.a. |
| Rifampicin | 05 | n.a. | n.a. | n.a. | n.a. | 34/61 (55.7%) | 27/61 (44.3%) | 77/130 (59%) | 53/130 (41%) | 3/22 (2.6%) | 19/22 (86.4%) | 1/51 (2%) | 50/51 (98%) |
| Vancomycin | 30 | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | 0/130 (0%) | 130/130 (100%) | n.a. | n.a. | n.a. | n.a. |
Abbreviations: Conc, concentration; R, resistance; S, susceptible; n/N(%), observed value/total tested value (percentage); n.a, not applicable.